SecBot SecBot
8-K ·Filed Mar 5, 2026

CRMD

CorMedix Inc.
BULLISH
Impact 8/10
Horizonweeks Processed8mo ago SEC0001213900-26-023881
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong revenue growth and profitability, driven by the Melinta acquisition and DefenCath sales, combined with the $75M buyback and reiterated guidance, suggest confidence in future performance. Traders should monitor upcoming Phase 3 data for Rezzayo in Q2 2026 as a key catalyst.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.30
T+0 close · Mar 5, 2026 · via day close
Latest settled
+34.13%
T+60 · $8.45
Vs SPY
+22.83%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $6.30entry
  2. T+1 · 9mo ago +2.54%α +3.85% · $6.46
  3. T+5 · 8mo ago +1.59%α +3.82% · $6.40
  4. T+20 · 8mo ago +11.90%α +15.69% · $7.05
  5. T+60 · 6mo ago +34.13%α +22.83% · $8.45
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CorMedix reported strong Q4 2025 financial results with $128.6 million in revenue, driven by DefenCath and the recent Melinta acquisition, and achieved full-year revenue of $311.7 million ($401.3 million pro forma). The company posted net income of $163.0 million and reiterated 2026 guidance of $300-$320 million in revenue and $100-$125 million in adjusted EBITDA, while announcing a $75 million share repurchase program.

Key Financial Metrics

Revenue
$128.6M
+312.2% YoY
EPS
$0.16
Guidance
$300-$320 million
maintained
Gross Margin
83.7%

Key Facts

  • Q4 2025 revenue was $128.6 million, up from $31.2 million in Q4 2024
  • Full-year 2025 revenue was $311.7 million, with pro forma revenue of $401.3 million
  • Q4 2025 net income was $14.0 million; full-year net income was $163.0 million
  • Adjusted EBITDA for Q4 2025 was $77.2 million, up from $15.3 million in Q4 2024
  • Company reiterated 2026 guidance: $300-$320 million revenue and $100-$125 million adjusted EBITDA
  • Board approved $75 million share repurchase program
  • Cash and short-term investments totaled $148.5 million at year-end

Financial Impact

Q4 revenue grew 312% YoY to $128.6M; full-year revenue was $311.7M with pro forma of $401.3M; net income turned from $17.9M loss in 2024 to $163.0M profit in 2025

revenuenet incomeepsebitdacash

Segment Breakdown

SegmentRevenue
DefenCath$91.2M
Melinta portfolio$37.4M

Risk Factors

  • Revenue growth is heavily influenced by the Melinta acquisition, making YoY comparisons difficult
  • Future performance depends on successful integration of Melinta and clinical trial outcomes
  • The $42.4M tax expense in Q4 was due to utilization of deferred tax assets, which may not recur

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-023881
Document: ea027968001-8k_cormedix.htm0001213900-26-023881
Document: 0001213900-26-023881-index-headers.html0001213900-26-023881
Document: 0001213900-26-023881-index.html0001213900-26-023881
Document: 0001213900-26-023881.txt0001213900-26-023881

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026